Amgen said Monday that it will buy the psoriasis pill Otezla from Celgene, which is selling the medicine to remove an antitrust obstacle from its planned merger with Bristol-Myers Squibb.
The purchase price for Otezla is $13.4 billion — higher than many analysts expected.
Bristol-Celgene investors will surely be pleased about fetching such a high price for what was essentially a forced product divestiture. Amgen shareholders might be a bit more wary about paying so much for Otezla, even though the drug is a good strategic fit.
About the Author Reprints
How will this merger effect patience who are on otezla who get the medication through specialty pharmacies
As Amgen is spending $13 billion to buy Otezla, the question “Will Amgen buy Alexion” won’t come up
https://news.alphastreet.com/amgen-amgn-to-acquire-celgenes-celg-otezla-for-13-4-billion-bmy-bristol-myers-squibb-celgene-merger-expected-to-close-by-end-of-2019/